Hsbc Holdings PLC Purchases 30,331 Shares of Integra LifeSciences Holdings Corporation $IART

Key Points

• Hsbc Holdings PLC significantly increased its stake in Integra LifeSciences Holdings Corporation by 303.6% in Q1, now owning 40,323 shares valued at $887,000.
• Multiple hedge funds have also adjusted their positions in Integra, with some increasing stakes significantly, highlighting institutional interest, as they collectively own 84.78% of the company's shares.
• Integra LifeSciences recently reported EPS of $0.45, exceeding estimates, but experienced a year-over-year revenue decline of 0.6% despite a favorable earnings outlook for FY 2025.

Hsbc Holdings PLC lifted its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 303.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,323 shares of the life sciences company's stock after purchasing an additional 30,331 shares during the quarter. Hsbc Holdings PLC owned 0.05% of Integra LifeSciences worth $887,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. lifted its stake in Integra LifeSciences by 2.5% in the first quarter. Principal Financial Group Inc. now owns 433,924 shares of the life sciences company's stock valued at $9,542,000 after acquiring an additional 10,492 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new stake in Integra LifeSciences in the first quarter valued at $251,000. Victory Capital Management Inc. lifted its stake in Integra LifeSciences by 1,067.6% in the first quarter. Victory Capital Management Inc. now owns 147,982 shares of the life sciences company's stock valued at $3,254,000 after acquiring an additional 135,308 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Integra LifeSciences by 3.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company's stock valued at $872,000 after acquiring an additional 1,437 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in Integra LifeSciences by 3,595.1% in the first quarter. GAMMA Investing LLC now owns 23,353 shares of the life sciences company's stock valued at $5,140,000 after acquiring an additional 22,721 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company's stock.

Integra LifeSciences Stock Performance

NASDAQ:IART traded up $0.63 during mid-day trading on Thursday, reaching $15.76. 789,147 shares of the company's stock were exchanged, compared to its average volume of 1,045,029. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.73 and a current ratio of 1.23. Integra LifeSciences Holdings Corporation has a one year low of $11.06 and a one year high of $27.13. The firm has a market capitalization of $1.23 billion, a PE ratio of -2.42, a price-to-earnings-growth ratio of 0.85 and a beta of 1.20. The business's fifty day simple moving average is $13.25 and its two-hundred day simple moving average is $15.89.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its earnings results on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.43 by $0.02. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The firm had revenue of $415.61 million for the quarter, compared to analyst estimates of $395.06 million. During the same period last year, the firm earned $0.63 EPS. The business's quarterly revenue was down .6% compared to the same quarter last year. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, JMP Securities cut their price target on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, Integra LifeSciences presently has a consensus rating of "Reduce" and an average target price of $18.43.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.